These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22246948)

  • 21. Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population.
    Poli D; Lip GY; Antonucci E; Grifoni E; Lane D
    J Cardiovasc Electrophysiol; 2011 Jan; 22(1):25-30. PubMed ID: 20653814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stroke due to atrial fibrillation in a population-based stroke registry (Ludwigshafen Stroke Study) CHADS(2) , CHA(2) DS(2) -VASc score, underuse of oral anticoagulation, and implications for preventive measures.
    Palm F; Kleemann T; Dos Santos M; Urbanek C; Buggle F; Safer A; Hennerici MG; Becher H; Zahn R; Grau AJ
    Eur J Neurol; 2013 Jan; 20(1):117-23. PubMed ID: 22788384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CHADS(2) and CHA(2)DS (2)-VASc score of patients with atrial fibrillation or flutter and newly detected left atrial thrombus.
    Wasmer K; Köbe J; Dechering D; Milberg P; Pott C; Vogler J; Stypmann J; Waltenberger J; Mönnig G; Breithardt G; Eckardt L
    Clin Res Cardiol; 2013 Feb; 102(2):139-44. PubMed ID: 22983022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (
    Patti G; Lucerna M; Pecen L; Siller-Matula JM; Cavallari I; Kirchhof P; De Caterina R
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28736385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?
    Ruiz-Nodar JM; Marín F; Roldán V; Valencia J; Manzano-Fernández S; Caballero L; Hurtado JA; Sogorb F; Valdés M; Lip GY
    Circ Cardiovasc Interv; 2012 Aug; 5(4):459-66. PubMed ID: 22787018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
    Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
    Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation.
    Myat A; Ahmad Y; Haldar S; Tantry US; Redwood SR; Gurbel PA; Lip GY
    Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):1029-49. PubMed ID: 23984927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data.
    Hughes M; Lip GY;
    Thromb Haemost; 2008 Feb; 99(2):295-304. PubMed ID: 18278178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation.
    Jover E; Roldán V; Gallego P; Hernández-Romero D; Valdés M; Vicente V; Lip GY; Marín F
    Rev Esp Cardiol (Engl Ed); 2012 Jul; 65(7):627-33. PubMed ID: 22609214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.
    Lip GYH; Banerjee A; Boriani G; Chiang CE; Fargo R; Freedman B; Lane DA; Ruff CT; Turakhia M; Werring D; Patel S; Moores L
    Chest; 2018 Nov; 154(5):1121-1201. PubMed ID: 30144419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
    Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antithrombotic management in atrial fibrillation].
    Fauchier L; Taillandier S; Clementy N
    Rev Prat; 2013 Feb; 63(2):199, 201-6. PubMed ID: 23513780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation.
    Overvad TF; Larsen TB; Albertsen IE; Rasmussen LH; Lip GY
    Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1619-29. PubMed ID: 24215192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy.
    Lip GY; Skjøth F; Nielsen PB; Larsen TB
    Thromb Haemost; 2015 Oct; 114(4):826-34. PubMed ID: 26223245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stroke mechanism in patients with non-valvular atrial fibrillation according to the CHADS2 and CHA2 DS2 -VASc scores.
    Cha MJ; Kim YD; Nam HS; Kim J; Lee DH; Heo JH
    Eur J Neurol; 2012 Mar; 19(3):473-9. PubMed ID: 21972975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.
    Zhu WG; Xiong QM; Hong K
    Tex Heart Inst J; 2015 Feb; 42(1):6-15. PubMed ID: 25873792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: A systemic review and meta-analysis.
    Xiong Q; Chen S; Senoo K; Proietti M; Hong K; Lip GY
    Int J Cardiol; 2015 Sep; 195():237-42. PubMed ID: 26048384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients.
    Winkle RA; Mead RH; Engel G; Kong MH; Patrawala RA
    Europace; 2014 Feb; 16(2):195-201. PubMed ID: 24036378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.